FOCUS
Swixx BioPharma GEOGRAPHIC AND THERAPEUTIC FOCUS
While today Swixx BioPharma is primarily focused on the CEE region, Swixx BioPharma anticipates to
further expand to Russia / CIS countries, and later possibly to Western Europe, Middle East or Africa.
That said, Swixx BioPharma’s focus is in the following therapeutic areas:
•
Modern, high tech, professionally-positioned products with a compelling medical proposition
(evidence based medicine / significant clinical impact), especially in oncology/hematology,
nephrology, transplantation medicines, GI and other specialty.
•
Rare disease / orphan medicines - new, dedicated business unit formed as of December, 2018
•
OTCs / Open Market preferably established brands or products with Unique Selling Propositions
•
Out of pocket / largely non-reimbursed products, in areas of critical unmet needs
•
Products with rapid regulatory pathways: Medical Devices / Food Supplements / Cosmetics and
products with existing registrations
•
Selective Purchase of existing brands or platforms that carefully complement our partners
portfolios
Swixx BioPharma is focused on the CEE region
•
Albania
•
Bosnia and Herzegovina
•
Bulgaria
•
Croatia
•
Czech Republic
•
Estonia
•
Hungary
•
Kosovo
•
Latvia
•
Lithuania
•
Montenegro
•
North Macedonia
•
Poland
•
Romania
•
Russia
•
Serbia
•
Slovakia
•
Slovenia
This region comprise 121 million people and a pharmaceutical market of 15.9 billion Euros. Their
economies currently are amongst the least developed in Europe, but they show considerable promise
and boast well-educated and cultured people. Many western healthcare companies chose not to
enter these markets, but nonetheless wish to have their products present and represented by a
professional, compliant and competent regional partner. Swixx BioPharma aims to fill this need and to
bring modern medicines to the people of the region.
A Swiss-based Pharmaceutical Company
© 2019 Swixx Biopharma SA. All rights reserved. Terms of Use. Privacy Policy
Formerly known as
